SynthesisFrontiers in pharmacology2023
Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies.
Synthesis in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 40 citations in OpenAlex.
- Nano-silymarin combined with methylene blue photodynamic therapy versus monotherapies of head and neck squamous cell carcinoma: in-vitro study.BMC cancer · 2026Article
- Effect of Loading Strategy on Methylene Blue Encapsulation in Ethosomes: A Comparative Study of Aqueous and Ethanol Phases.Methods and protocols · 2026Article
- Iodinated Near-Infrared Dyes as Effective Photosensitizers for the Photodynamic Eradication of Amphotericin B-Resistant Candida Pathogens.Molecules (Basel, Switzerland) · 2025Article
- Light, Dyes, and Action: Photodynamic Inactivation ofBiology · 2025Article
- Synthesis of New Phenothiazine/3-cyanoquinoline and Phenothiazine/3-aminothieno[2,3-b]pyridine(-quinoline) Heterodimers.International journal of molecular sciences · 2025Article
- Enhanced Cancer Radiosensitization via Energy Transfer from Eu-Doped GdFACS applied materials & interfaces · 2025Article
- Advances in Photodynamic Treatment of Precancerous and Cancerous Gynecological Diseases.Cancers · 2025Review
- Targeting inflammasomes as an immunotherapeutic strategy for cancer.Journal of translational medicine · 2025Review
- Drug Repurposing and Nanotechnology for Topical Skin Cancer Treatment: Redirecting toward Targeted and Synergistic Antitumor Effects.ACS pharmacology & translational science · 2025Review
- Efficacy of EGFR Targeting IR700-Related Photoimmunotherapy in Preventing Growth of Cancer Cells-A Systematic Review.Cancer management and research · 2025Review
- Advancing Cancer Treatment: Innovative Materials in PDT and Diagnostic Integration.International journal of nanomedicine · 2025Review
- Spectroscopic Study of Methylene Blue Interaction with Coenzymes and its Effect on Tumor Metabolism.Sovremennye tekhnologii v meditsine · 2025Article
- Photodynamic Therapy: A Novel Approach for Head and Neck Cancer Treatment with Focusing on Oral Cavity.Biological procedures online · 2024Review
- Cellular Aging and Senescence in Cancer: A Holistic Review of Cellular Fate Determinants.Aging and disease · 2024Review
- Polydopamine-Coated Liposomes for Methylene Blue Delivery in Anticancer Photodynamic Therapy: Effects in 2D and 3D Cellular Models.International journal of molecular sciences · 2024Article
- Recent advances in cell membrane-coated porphyrin-based nanoscale MOFs for enhanced photodynamic therapy.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.